Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2020 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Team from the UFS Microbiology department
From the Department of Microbiology and Biochemistry, were from the left, front: Dr Mariana Erasmus, Prof Martie Smit, Samantha McCarlie; back: Dr Carmien Tolmie; Samantha McCarlie, Prof Dirk Opperman, and Prof Robert Bragg. They believe publishing in high-impact factor journals reflects the quality of research delivered by the department.

Researchers in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS) published their work in four impact factor eleven journals in 2019/2020, and a fifth was accepted for publication in a journal with impact factor twelve in 2020. 

Two articles were published in Nature Communications, one in Drug Resistance Updates and one in Natural Product Reports. A fifth article is already available as an accepted article at Angewandte Chemie. Researchers in the department work on very diverse topics, as reflected in the titles of these articles: ‘A chemo-enzymatic oxidation cascade to activate C–H bonds with in situ generated H2O2’; ‘Native roles of Baeyer–Villiger monooxygenases in the microbial metabolism of natural compounds’; ‘The genome of a subterrestrial nematode reveals adaptations to heat’; ‘Molecular basis of bacterial disinfectant resistance’; and ‘CYP505E3 – a novel self‐sufficient ω‐7 in‐chain hydroxylase’.

Publishing in journals with a high impact factor is quite an achievement. Publishing in a journal with an impact factor of 3 is considered good and in most fields of study, publishing in journals with an impact factor of 10 or more is regarded as excellent. Impact factors are used to measure the importance of a journal by counting the number of times articles were cited in a certain time period. 

According to Prof Martie Smit, Head of the department, this is a reflection of the quality of research delivered by the department. “It is difficult and takes a lot of time and resources to publish in such high-impact journals.”

Contributing to their success in the department, is the work of their collaborators as well as the quality international postdoctoral researchers the department manages to attract with their emphasis on quality research.

Another highlight in the publication of these articles was that members of the department were corresponding authors of four of the five articles – meaning that the research was conducted in and driven from their laboratories, with UFS researchers taking primary responsibility for the preparation of the manuscripts and communicating with the editors of the journals.

Impacting society

Besides publishing in journals with high impact factors, these researchers are also making a difference to society. Prof Robert Bragg contributed to the study focusing on quality disinfectants. 

We are all aware of the danger of developing resistance to antibiotics. According to Prof Bragg, it is estimated that by 2050, 25 million people could be dying from antibiotic resistance-related bacterial infections per year. He says one of the best options to control diseases – not only bacterial diseases, but also viral diseases such as the Covid-19 outbreak – is good biosecurity and the use of good-quality disinfectants.

Researchers working on this study are trying to understand the development of resistance in bacteria to disinfectants. “This research group is currently investigating the ways in which bacteria become resistant to different high-quality disinfectants. The aim of this work is to discover new methods of resistance and then try to prevent bacteria from becoming resistant to commonly used disinfectants. One of the first aspects that needs investigation is to understand the methods of transfer of genetic information between bacteria. This work formed the basis of the review article written with master’s student Samantha McCarlie on transfer of genes that could code for disinfectant resistance in bacteria,” says Prof Bragg.

Studies about a nematode species discovered 1,3 km deep in a gold mine in Welkom and its ability to survive in extreme environments, made headlines about nine years ago. More extensive research has been performed on deep-space exploration of nematodes surviving extreme environments and were published in Nature Communications. Dr Mariana Erasmus, Assistant Director in the department and Technology Innovation Agency/UFS Saense Platform manager, says the study published in 2019 reveals these nematodes’ adaptation to heat and heat tolerance in an unusual ecosystem isolated from the surface biosphere. More studies on this can help humans learn how to adapt to a warming climate. 

TIA is an agency of the Department of Science and Innovation.

Three of the articles are from the Biocatalysis and Structural Biology group of Prof Dirk Opperman, Prof Martie Smit, and Dr Carmien Tolmie. Biocatalysis is a form of green chemistry that aims to produce chemicals in an environmentally friendly and sustainable manner. The research of the group focuses on using enzymes (proteins performing specialised chemical reactions) to insert an oxygen atom at a specific position in a starting material. Such reactions are difficult to perform using purely organic chemistry. 

The end products are value-added compounds of interest to, among others, the flavour and fragrance industry, which place a high premium on natural products. The work on the novel in‐chain hydroxylase was also patented internationally, because it can be used for the synthesis of a valuable flavour compound.
 
More to come

Besides the commitment of the team in Microbiology, it took multiple institutions, dedicated postdoctoral students, as well as time and money to publish this number of articles in high-impact journals in just over a year. With its 100-plus researchers varying from student researchers to NRF-rated scientists, everyone in the Department of Microbial, Biochemical and Food Biotechnology strives to produce high-quality research. 

And they promise, there is more to come. Watch this space …

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept